No new CDC stage C and two CDC stage B events were recorded (bronchopneumonia in the short cycle therapy group and bronchitis in the continuous therapy group) and no significant differences were noted between groups in CD4% or CD4 cell count (table 2). Here, CD4 is linked to bronchial disorder.